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Infectious keratitis in patients undergoing Boston Type 1 keratoprosthesis (Boston KPro)
procedure: case series
Ceratite infecciosa em pacientes submetidos ao implante de ceratoprótese
Boston Tipo I: série de casos
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ABSTRACT
Description of two cases of infectious keratitis in patients after Boston Type 1
keratoprosthesis (Boston KPro) implantation. The first case refers to a patient that
had the device indicated due to limbal deficiency secondary to severe dry eye who
presented a fungal infection by Aerobasidium pullulans that was successfully treated
with amphotericin B eye drops. The second case reports a patient with Boston KPro
implantation due to previous corneal transplant rejection showing bacterial keratitis
in the fourth postoperative month. The etiologic agent was identified as Streptococcus
sp and topical treatment with vancomycin was effective. The importance of posto-
perative surveillance in Boston KPro eyes is discussed.
Keywords: Cornea/surgery; Corneal diseases/surgery; Keratitis; Prosthesis implan-
tation; Visual acuity; Preoperative care; Human; Female; Aged, 80 and over; Case
reports
RESUMO
Descrição de dois casos de ceratite infecciosa em pacientes submetidos a implante de
ceratoprótese Boston Tipo 1 (Boston KPro). O primeiro caso refere-se a uma paciente na
qual o dispositivo foi indicado por deficiência límbica secundária a olho seco grave, no
qual foi identificado infecção fúngica por aerobasidium pullulans, tratada com
sucesso com colírio de anfotericina B. O segundo caso reporta uma paciente com
implante de Boston KPro por falências de transplantes de córnea prévios, que apre-
sentou ceratite bacteriana no quarto mês pós-operatório. O agente etiológico identi-
ficado foi Streptococcus sp e o tratamento tópico com vancomicina foi eficaz.
Discute-se a importância da vigilância pós-operatória em olhos submetidos ao im-
plante de ceratoprótese.
Descritores: Córnea/cirurgia; Doenças da córnea/cirurgia; Ceratite; Implante de prótese;
Acuidade visual; Cuidados pré operatórios; Humanos; Feminino; Idoso de 80 anos ou
mais; Relatos de casos
INTRODUCTION
Keratoprosthesis (KPro) surgery is usually indicated for patients
with multiple corneal transplant rejection and also for patients
with cicatricial ocular surface disease (autoimmune diseases, che-
mical and thermal eye burns, etc)(1). Considering the severity of
ocular surface involvement in these patients, as well as the nume-
rous surgical procedures that they have undergone, the high risk of
postoperative complications in these patients is understood. These
complications include: glaucoma(1), tissue melting leaking aqueous
humor(2), device extrusion, chronic inflammation and retroprothetic
membrane formation(3), retinal detachment(4), macular edema, in-
fectious keratitis and bacterial endophthalmitis(5-6).
Boston type 1 KPro is used in patients with relatively normal
eyelid function and ability to maintain the ocular surface “wet”. After
Boston KPro implantation, the corneal surface becomes vulnerable
to evaporative forces. Epithelial defects, stromal thinning, dellen
formation and melting, especially in eyes with underlying inflamma-
tory disease may occur(7).
Since the beginning of Boston KPro use, one of the problems
related to the device was dehydration of ocular surface. This issue
was successfully solved with the use of therapeutic contact lenses in
the eyes implanted with Boston Type 1 KPro. However, the use of
contact lens increases the risk of corneal infection and colonization
and, therefore, it requires additional care of physician and patient.
The use of therapeutic contact lens improved quality of the ocular
surface in Boston KPro users and was also responsible for increased
indications of this procedure worldwide.
The increased risk of ocular infection in patients with tear film
dysfunction and in patients receiving chronic topical corticosteroids
justified the need to establish a prophylactic antibiotic regimen for
patients with Boston Type 1 KPro implant. Previously, the prophy-
lactic regimen consisted of polymyxin-trimethoprim, gentamicin
or ofloxacin. However, the large number of infections even using
this prophylactic regimen caused its modification to the use of
broad-spectrum antibiotics. Currently, vancomycin is used in the
United States as a prophylactic antibiotic regimen of choice for
Boston KPro patients(8).
The prophylactic use of broad-spectrum antibiotics associated
with contact lens predisposes to fungal colonization and infection in
Boston KPro eyes(9). Warm and humid environments are other pre-
disposing factors for fungal infection and colonization(9). This weather
pattern is very common in Brazil.
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Figure 1.  Opacity at the interface between anterior plate of the KPro and donor corneal button. Note the epithelial denuding area evidenced
by fluorescein staining under cobalt blue light.
Figure 2.  Corneal infiltrate in the full extension of the interface between anterior plate of KPro and donor corneal button.
Although recommended by the manufacturer, prophylaxis with
vancomycin eyedrops has some limitations in our country, such as
cost of handling and storage difficulties. The Cornea and External Eye
Disease Sector, Department of Ophthalmology of UNIFESP uses 0.5%
moxifloxacin as prophylaxis associated with programmed replace-
ment of in patients with Boston Type 1 keratoprosthesis implantation.
CASE REPORT
CASE 1
TAC, a 94-year old female diagnosed with limbic failure secon-
dary to severe dry eye, underwent Boston Type 1 keratoprosthesis
implantation in the right eye.
According to postoperative routine of the service, the patient
was assessed on the first postoperative follow-up, after two weeks
and then monthly. The postoperative regimen included 0.5% mo-
xifloxacin as prophylaxis, topical steroids, lubricating eye drops and
contact lenses (Kontur Contact Lens, Richmond, CA). This hydro-
philic contact lens was suggested by the Boston KPro manufacturer
and its replacement programmed to every three months. The steroids
were reduced gradually according to ocular inflammation, but
maintained one drop daily. The authors cannot assure about pa-
tients compliance regarding the use of antibiotic and the prophy-
lactic regimen, but they were exhaustively informed about it.
Cultures of the conjunctiva and of the discarded therapeutic con-
tact lenses were collected for routine monitoring.
Two months after surgery, the patient had a positive culture for
fungus Aerobasidium pullulans in the analysis of contact lenses.
However, this analysis did not show any visible fungal colonization
in the contact lens and the biomicroscopy showed no evidence
suggesting infection.
As there were no obvious signs of eye infection and nor Boston
Kpro or contact lens colonization, an expectant management was
used. Two weeks after the positive culture found in the therapeutic
contact lens, the patient developed a slight opacity extending from
3 to 5 hours at the interface between the anterior plate of kerato-
prosthesis and the donor corneal button (Figure 1).
At that time, due to the presence of visible corneal infiltration,
antifungal eyedrops were initiated. Patient was treated with 0.15%
amphotericin B eyedrops q.i.d.
The patient was subsequently monitored and showed regression
of corneal opacity.
CASE 2
TMF, an 83-year old female diagnosed with two previous episodes
of corneal transplant failure, underwent Boston Type 1 keratoprosthe-
sis implantation in the right eye.
The same postoperative care previously described for the pa-
tient mentioned above was conducted in this patient.
Four months after surgery, the patient developed corneal opa-
city on the entire interface between the anterior plate of Boston KPro
and donor corneal button. There was denuded epithelium in the
74(2)14.pmd 20/6/2011, 16:18128
NASCIMENTO  HM, ET AL .
129Arq Bras Oftalmol. 2011;74(1):127-9
opaque area, as shown in figure 2. The culture of corneal scrapings
from the affected area was positive for Streptococcus sp.
At that point, considering the continued use of 0.5% moxiflo-
xacin concomitant with the corneal infiltrate onset and the fact that
the microorganism was resistant to moxifloxacin, treatment with
5% vancomycin eye drops was initiated. There was gradual impro-
vement after seven days of treatment, with disappearance of the
corneal infiltrate and epithelial healing.
DISCUSSION
As far as we know, this is the first report of fungal isolation in the
ocular surface of patients after Boston Type 1 keratoprosthesis im-
plantation in Brazil. According to Barnes et al., the rate of fungal coloni-
zation in Boston KPro eyes is about 10%(9). This incidence was similar
even before the use of broad-spectrum antibiotics and contact
lenses(5), and was also similar to those found in normal conjunctival
flora, with a fungal colonization ranging from 5 to 25%(9). Fungal
infections cannot be predicted by routine periodic cultures of the
ocular surface of Boston KPro eyes as reported by Barnes et al that
fungal colonization fluctuates spontaneously over the time(9).
In the first case, fungal growth was found two months after Boston
Type 1 keratoprosthesis implantation. This might have been favored
by the tropical climate in Brazil, the prophylactic regimen (broad
spectrum antibiotic and steroids) and the use of contact lenses.
Antifungal prophylactic regimen should not be recommen-
ded for all Boston keratoprosthesis users due to the low incidence
of fungal infections and the lack of correlation between the routine
surveillance cultures and the emergence of infections(9). Howe-
ver, initiation of aggressive antifungal regimen is recommended
in three circumstances: visible corneal colonization; visible colo-
nization in the therapeutic contact lens and presence of active
infection.
As the patient developed a visible corneal infiltration, the anti-
fungal treatment was initiated, resulting in clinical improvement.
In the second case, a bacterial infection was diagnosed in the
routine postoperative assessment. The rapid identification of the cau-
sative agent and the initiation of appropriate treatment were crucial
to good clinical response and maintenance of keratoprosthesis.
The use of contact lens, trauma, ocular surface disease and corneal
surgery are the major risk factors for infectious keratitis(10).
Among the four main risk factors for the development of
infectious keratitis, the second patient of the case series showed
three of them. Importantly, the site most prone to developing
infectious keratitis in patients after Boston Type 1 keratoprosthesis
implantation is between anterior plate of prosthesis and the donor
button, where there is a virtual space in which the tear film distri-
bution is irregular, favoring the accumulation of tear and, conse-
quently, the proliferation of microorganisms.
Keratoprosthesis is a promising device in modern corneal
surgery. However, the high rate of risk factors for infections requi-
res a thorough postoperative care, with surveillance cultures and
routine monitoring visits. This case series is an example of the im-
portance to keep Boston KPro patients on an exhaustive and close
postoperative regimen in order to recognize the onset of infec-
tions. Any sign of infection should be promptly investigated and
tailored treated to promote greater durability of the device.
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